Get the Stockscreener App
9.20
4.31%
0.38
After Hours:
9.23
0.03
+0.33%
Cel-Sci Corp. stock is traded at $9.20, with a volume of 72,441.
It is up +4.31% in the last 24 hours and down -11.79% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$8.82
Open:
$8.89
24h Volume:
72,441
Relative Volume:
0.10
Market Cap:
$63.32M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-18.04
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
+6.60%
1M Performance:
-11.79%
6M Performance:
+33.10%
1Y Performance:
-71.07%
1-Day Range:
$8.6927
$9.2685
1-Week Range:
$8.44
$9.33
52-Week Range:
$1.98
$33.90
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
9.20 | 60.70M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
CEL SCI Corporation stock momentum explainedJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Will CEL SCI Corporation stock pay special dividendsJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Will CEL SCI Corporation price bounce be sustainableJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
What makes CEL SCI Corporation (LSR) stock appealing to growth investorsM&A Rumor & Real-Time Sentiment Analysis - newser.com
Will Cel Sci Corporation stock announce a stock splitEarnings Risk Summary & Long-Term Safe Return Strategies - newser.com
Will CEL SCI Corporation (LSR) stock split increase liquidity2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - newser.com
Will CEL SCI Corporation (LSR) stock remain on Wall Street radarMarket Activity Recap & Daily Stock Trend Watchlist - newser.com
Can CEL SCI Corporation (LSR) stock survive global slowdownJuly 2025 Decliners & Verified Swing Trading Watchlists - newser.com
Can Cel Sci Corporation stock withstand sector downturnsWeekly Market Report & Safe Capital Preservation Plans - newser.com
Is CEL SCI Corporation stock bottoming out2025 Year in Review & Low Drawdown Momentum Ideas - newser.com
What analysts say about CEL SCI Corporation stockStock Price Forecasts & Join 100,000+ Investors Already Learning - earlytimes.in
What does recent volatility data suggest for CEL SCI CorporationDay Trade & Weekly Breakout Watchlists - newser.com
Chart based analysis of CEL SCI Corporation trends2025 Short Interest & Verified Short-Term Trading Plans - newser.com
Why CEL SCI Corporation stock is a value investor pickMarket Rally & Consistent Growth Equity Picks - newser.com
How buyback programs support CEL SCI Corporation (LSR) stockMarket Activity Recap & Entry Point Confirmation Signals - newser.com
CEL-SCI Announces Pricing of $10 Million Public Offering - Investing News Network
CEL-SCI Co. (NYSE:CVM) Short Interest Down 26.3% in August - MarketBeat
Market reaction to CEL SCI Corporation’s recent newsJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
Understanding CEL SCI Corporation’s price movementMarket Growth Report & Long-Term Capital Growth Ideas - newser.com
What Fibonacci levels say about CEL SCI Corporation rebound2025 Year in Review & Low Drawdown Momentum Ideas - newser.com
Applying Elliott Wave Theory to CEL SCI CorporationBull Run & Target Return Focused Stock Picks - newser.com
IPO Launch: What is CEL SCI Corporations P E ratio telling usInflation Watch & Consistent Growth Equity Picks - khodrobank.com
Quarterly Risk: is cel sci corporation impacted by rising ratesCEO Change & Smart Investment Allocation Insights - خودرو بانک
Pattern recognition hints at CEL SCI Corporation upsideMarket Activity Summary & Trade Opportunity Analysis - newser.com
Resistance Check: How do insiders feel about CEL SCI Corporation2025 Growth vs Value & Capital Protection Trade Alerts - khodrobank.com
Evaluating CEL SCI Corporation with trendline analysis2025 Price Action Summary & Safe Swing Trade Setup Alerts - newser.com
Identifying reversal signals in CEL SCI CorporationChart Signals & Reliable Price Action Trade Plans - newser.com
Why CEL SCI Corporation is moving todayMarket Risk Report & Smart Investment Allocation Tips - newser.com
IPO Launch: What are DMC Global Incs technical support levelsMarket Trend Report & Accurate Buy Signal Notifications - خودرو بانک
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):